Ann: Trading Halt, page-117

The process for the successful development of the current Covid vaccines was completed so rapidly because of the MASSIVE amount of money thrown at it. That’s why Oxford had to pair up with AstraZeneca, and BioNTech with Pfizer. Off the top of my head I don’t know how much was spent by each of these companies on development, but I know Novavax got over a billion dollars in grants from the US government. This allowed fast-tracked regulatory submissions and approvals, overlapping phase 2 and 3 trials before all results were out, etc.

The Australian government will not support MIPS/Doherty vaccine development with anywhere near enough money to do this, that’s why I said they will need to find a big pharma partner to get this done. And I just don’t see how they could establish a partnership and get phase 3 trials done by the end of 2022, when they won’t even have immunogenicity results from phase 1/2 trials until probably mid next year.